No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients

Figures & data

Figure 1. Flow chart of the selection process of patients.

Figure 2. Kaplan-Meier estimate of breast cancer-free survival in relation to CYP2D6 genotype activity score. a) among tamoxifen-treated patients with invasive ER-positive tumors (LogRank, p_trend = 0.48). Adjusted HR_PM (0.50; 95% CI 0.07–3.82; p = 0.50) and adjusted HR_IM (1.00; 95% CI 0.47–2.11; p = 1.00) compared with EMs. b) among tamoxifen-treated patients with invasive ER-positive tumors who had not received chemotherapy (LogRank, p_trend = 0.70). c) among tamoxifen-treated patients with invasive ER-positive tumors who had not received chemotherapy and/or aromatase inhibitors (LogRank, p_trend = 0.49).

Table I. Patient characteristics for all 634 patients, and for the 333 tamoxifen-treated patients with ER-positive tumors (in gray).

Table II. Frequency of the CYP2D6 genotypes in all patients (n = 634), and for the 333 tamoxifen-treated patients with ER-positive tumors (in gray) with and without stratification according to CYP2D6 genotype activity score and CYP2D6 activity score. CYP2D6 genotype was missing for 18 of the 634 patients.